Provider Briefing: The Hydroxocobalamin Shortage in 2026

If your patients are reporting difficulty filling Hydroxocobalamin prescriptions, the cause is a well-documented national shortage that has been escalating since late 2025. This briefing covers the key facts you need to support prescribing decisions, manage patient expectations, and identify alternative treatment pathways.

Whether you prescribe Hydroxocobalamin for pernicious anemia, B12 deficiency secondary to malabsorption, or post-bariatric supplementation, the current supply disruption requires proactive clinical management.

Shortage Timeline

Here is the chronology of events affecting Hydroxocobalamin supply:

• Late 2018: The first major U.S. shortage occurred when Meridian Medical Technologies experienced significant production delays for the Cyanokit IV formulation, coupled with increasing demand. This prompted initial supply chain reviews across the industry.
• 2023-2024: Serb Pharmaceuticals (current Cyanokit manufacturer) placed batches on hold due to quality issues at their contract manufacturer related to sterility assurance processes. The FDA conducted reviews and allowed select batches to be released after testing confirmed they met sterility and endotoxin specifications.
• October 2025: The European Medicines Agency (EMA) reported that the Cyanokit supply shortage in Europe had been resolved.
• December 2025: Actavis Pharma (distributed by Hikma Farmaceutica) — the primary U.S. manufacturer of generic Hydroxocobalamin 1000 mcg/mL IM injection — reported the product as temporarily unavailable due to a shortage of active pharmaceutical ingredient (API). Estimated resupply: June 2026.
• Early 2026: The shortage continues. ASHP and FDA maintain Hydroxocobalamin on their current drug shortage lists.

Prescribing Implications

The shortage creates several clinical decision points for prescribers:

Patients Currently on Hydroxocobalamin IM

For patients on maintenance therapy (typically 1 mg IM every 2-3 months), the immediate concern is continuity of care. Options include:

• Switching to Cyanocobalamin IM: The most straightforward substitution. Cyanocobalamin is available from multiple manufacturers and effectively treats B12 deficiency. The key difference is dosing frequency — Cyanocobalamin requires monthly injections rather than every 2-3 months due to lower tissue retention.
• Compounded Hydroxocobalamin: Compounding pharmacies can prepare Hydroxocobalamin injections in various concentrations (e.g., 10 mg/mL, 20 mg/mL). This may be preferred for patients who have responded well to Hydroxocobalamin specifically.
• High-dose oral Cyanocobalamin (1,000-2,000 mcg/day): Evidence supports this approach for maintenance in clinically stable patients, including those with pernicious anemia. About 1% of oral B12 is absorbed passively, independent of intrinsic factor. This option works best for patients without active neurological symptoms who prefer to avoid injections temporarily.

New Patients Requiring B12 Replacement

For new diagnoses of B12 deficiency requiring injectable therapy, consider initiating with Cyanocobalamin rather than Hydroxocobalamin to avoid prescribing a medication the patient may not be able to fill.

Neurological Considerations

Patients with subacute combined degeneration, peripheral neuropathy, or other neurological manifestations of B12 deficiency warrant injectable B12 to ensure reliable absorption and adequate tissue levels. Oral supplementation may be insufficient in these cases. If Hydroxocobalamin is unavailable, Cyanocobalamin IM or compounded Methylcobalamin are the preferred alternatives.

Current Availability Picture

As of early 2026:

• Hydroxocobalamin 1000 mcg/mL IM (generic): Unavailable from Actavis/Hikma. No alternative generic manufacturer has announced increased production.
• Cyanocobalamin IM: Available from multiple manufacturers including Hikma, American Regent, and Amneal. Supply is stable but should be monitored.
• Compounded Hydroxocobalamin: Available from licensed compounding pharmacies. Supply is generally stable as these pharmacies source API independently.
• Cyanokit IV (5 g): Limited availability. Serb Pharmaceuticals continues to manage quality-related supply constraints. FDA has released select batches for emergency use.

Cost and Access Considerations

For your patients who are cost-sensitive:

• Generic Hydroxocobalamin IM (when available): $20-$58 cash price; most insurance plans cover with low copay ($5-$20)
• Cyanocobalamin IM: Under $15 with discount coupons; widely covered by insurance
• Compounded Hydroxocobalamin: $30-$80 per multi-dose vial; may not be covered by insurance
• High-dose oral B12: $5-$15/month OTC; no prescription needed

For patients facing financial hardship, resources like NeedyMeds and RxAssist can help identify assistance programs. Discount coupons from GoodRx and SingleCare can reduce costs for generic formulations. For more information, refer patients to our guide on saving money on Hydroxocobalamin.

Tools and Resources for Providers

Medfinder for Providers

Medfinder for Providers helps you and your staff quickly identify pharmacies with Hydroxocobalamin in stock. You can search by medication name and location to direct patients to pharmacies that currently have availability. This reduces patient callbacks and failed fill attempts.

ASHP Drug Shortage Resource Center

The ASHP maintains the most up-to-date information on Hydroxocobalamin shortage status, including manufacturer updates and alternative therapy recommendations. Check their current shortages page regularly.

Compounding Pharmacy Networks

If you don't already have a relationship with a compounding pharmacy, consider establishing one. National compounding pharmacies like Empower Pharmacy can prepare Hydroxocobalamin injections and ship to patients across the country. Having a compounding option ready gives you a reliable fallback during shortages.

Looking Ahead

The Hydroxocobalamin shortage is expected to continue through at least mid-2026. Key factors to watch:

• API supply recovery: The root cause of the generic shortage is active ingredient availability. Until the API supply chain stabilizes, manufacturing cannot resume.
• Potential new market entrants: The shortage may incentivize additional generic manufacturers to enter the market, though regulatory approval timelines mean any new entrant is unlikely before late 2026 or 2027.
• Cyanocobalamin supply stability: As more patients switch to Cyanocobalamin, monitor for any secondary supply pressure on that product.

Final Thoughts

The Hydroxocobalamin shortage requires proactive management from prescribers. Key takeaways:

1. Cyanocobalamin IM is the most readily available alternative for B12 deficiency
2. Compounded Hydroxocobalamin is available for patients who specifically need this formulation
3. High-dose oral B12 may be appropriate for stable maintenance patients
4. Neurological cases should receive injectable therapy regardless of formulation
5. Use Medfinder for Providers to help patients locate available stock

For a patient-facing version of this information, you can direct patients to our patient shortage update. For clinical questions about Hydroxocobalamin, see our posts on drug interactions and side effects.